LIPOPROTEIN TYPES--Lp SYSTEM Lp(a) HYPERLIPOPROTEINEMIA
4
1
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Daliadsorber
Research Leaders
6 sponsors active, led by Kaneka Pharma Europe N.V.
Related Conditions
Often studied with 7 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Elevated Lipoprotein(a) in Hospital Staff
Atlantic Lipid Lowering Treatment Optimization Program
Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes
Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter
Research Network
Common Treatments
- Daliadsorber1
- Supportive Care1
- Monetlipoprotein Filter1
Active Sponsors
- Kaneka Pharma Europe N.V.1
- Changi General Hospital1
- Regeneron Pharmaceuticals, Inc.1
- Atlantic Health System1
- Fresenius Medical Care Deutschland GmbH1
Top Investigators
Nephrologische Gemeinschaftspraxis Dialysezentrum/Lipidzentrum
Technische Universität Dresden
Singhealth Foundation
University Regensburg Department Clinical Chemistry and Laboratory Medicine
Nierenzentrum Mannheim
Related Conditions
- High Density Lipoprotein Deficiency1
- Hypercholesterolemia1
- Hypercholesterolemia Familial1
- Lowdensitylipoidtype Hyperlipoproteinemia1
- Apolipoprotein B 100 Familial Defective1